"We'd like to congratulate Dr. Chlebowski on this well-deserved honor," said David I. Meyer, Ph.D., president and CEO of LA BioMed. "Dr. Chlebowski has been at the forefront of breast cancer therapy and prevention for nearly two decades, and the significant discoveries he's made in this area continue to help women who suffer from this disease."
Dr. Chlebowski is best known for his work on significant clinical trials related to breast cancer prevention and therapy and women's health. He reported results of the Women's Intervention Nutrition Study (WIINS), a multi-center adjuvant trial where a lifestyle intervention reduced breast cancer recurrence, at the 2005 ASCO Annual Meeting Plenary Session. As a Women's Health Initiative (WHI) investigator, Dr. Chlebowski led reports on estrogen alone and estrogen plus progestin influence on cancer endpoints. The findings of adverse effects of combined estrogen plus progestin use on breast cancer and several other diseases have substantially decreased use of menopausal hormone therapy worldwide with associated reduction in breast cancer incidence.
"The results have been extremely gratifying—it likely means that thousands of women were spared a breast cancer diagnosis," said Dr. Chlebowski.
More recent analyses in the WHI randomized trial evaluating estrogen alone in women with prior hysterectomy found the surprising outcome of lower breast cancer incidence with hormone use. In addition, analyses in the WHI identified potential metformin (a commonly used diabetes therapy) and bisphosphonate (used for osteoporosis therapy) to reduce breast cancer risk as well.
"Our research is primarily directed at evaluating new paradigms for preventing breast cancer, a disease which has claimed the lives of so many," said Dr. Chlebowski.
Provided by Los Angeles Biomedical Research Institute at Harbor
This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.
